Last reviewed · How we verify
NCT06958783
Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer
trial testing Blood lipid monitoring in breast cancer patients during chemotherapy in Breast Neoplasms in 56 participants. Completed in 28 February 2025.
28 February 2025
Quick facts
| Lead sponsor | Cancer center Stefan Kukura Hospital Michalovce |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 5 March 2023 |
| Primary completion | 28 February 2025 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across Slovakia |
Drugs / interventions tested
- Blood lipid monitoring in breast cancer patients during chemotherapy
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Lipid Profile — all drugs for Lipid Profile →
- Dyslipidemia — all drugs for Dyslipidemia →
Sponsor
Cancer center Stefan Kukura Hospital Michalovce
Who can join
Adults 18 to 80, female only, with Breast Neoplasms or Lipid Profile. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Detection of changes in the lipid profile in early-stage breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prospective evaluation of chemotherapy-induced dyslipidemia in early breast cancer: implications for cardiovascular risk.
Rusinova L, Medvedieva J, Santova Z, Kozarova M. · · 2025 · PMID 41602405 · DOI 10.3389/fonc.2025.1677835
Verify or expand the search:
- PubMed search for NCT06958783
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06958783 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer center Stefan Kukura Hospital Michalovce
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06958783.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing